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Abstract
α6β4 integrin plays pivotal roles in cancer progression in several types of cancers. Our previous 
study using N-glycan-manipulated cell lines demonstrated that defects in N-glycans or decreased 
β1,6GlcNAc-branched N-glycans on β4 integrin suppress β4 integrin-mediated cancer cell adhesion, 
migration, invasion, and tumorigenesis. Furthermore, immunohistochemical analysis has shown 
that colocalization of β1,6GlcNAc-branched N-glycans with β4 integrin was observed in cutaneous 
squamous cell carcinoma (SCC) tissue. However, until now there has been no direct evidence that 
β1,6GlcNAc-branched N-glycans are upregulated on β4 integrin in cutaneous SCC. In the present 
study, we performed an ELISA analysis of β1,6GlcNAc-branched N-glycans on β4 integrins as well 
as β4 integrins in cell lysates from human normal skin and cutaneous SCC tissues. The SCC sam-
ples showed a 4.9- to 7.4-fold increase in the ratio of β1,6GlcNAc-branched N-glycans to β4 integrin 
compared with normal skin samples. These findings suggest that the addition of β1,6GlcNAc-
branched N-glycans onto β4 integrin was markedly elevated in cutaneous SCC tissue compared to 
normal skin tissue. The value of β1,6GlcNAc-branched N-glycans on β4 integrin may be useful as 
a diagnostic marker associated with cutaneous SCC tumor progression.
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Introduction
α6β4 integrin is a principle receptor for laminin, 
an extracellular matrix protein. Binding of α6β4 in-
tegrin to the basement membrane protein laminin-332 
plays essential roles in the formation of stable adhe-
sion complex hemidesmosomes in the skin1-3). The 
α6β4 integrin is a heterodimeric transmembrane pro-
tein consisting of α6 and β4 subunits. β4 integrin has 
a unique longer cytoplasmic domain (> 1,000 amino 
acid residues) compared to other β integrin subunits 
(< 50 amino acid residues), and this unique domain in-
teractings with other hemidesmosome component pro-
teins such as plectin, BP180, and BP2304). For this 
reason, α6β4 integrin has long been regarded as a 
component in the formation of tight adhesion. How-
ever, recent studies have shown that increased expres-
sion of α6β4 integrin is correlated with tumor malig-
nancy and poor survival of patients in several types of 
cancers including cutaneous squamous cell carcinoma 
(SCC)5-7). Furthermore, many reports have revealed 
that α6β4 integrin plays key roles in cancer progres-
sion by promoting cancer cell migration, invasion, 
proliferation, metastasis, and tumorigenesis3). These 
functions of α6β4 integrin are dynamically regulated 
by post-translational modifications, phosphorylation 
and N-glycosylation on β4 integrin4,8-10).
Glycosylation is the most common post-transla-
tional modification of proteins and has profound ef-
fects on protein folding, stability, solubility, secretion, 
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transport, and interaction with other proteins11,12).　
Glycosylation regulates various functions of proteins 
and is involved in various physiological and pathologi-
cal events. Protein glycosylation varies according to 
age, sex, and lifestyle, but overall profiles are consis-
tent in healthy individuals12,13). In contrast, aberrant 
glycosylation of proteins is often associated with ma-
lignant transformation14).
β1,6GlcNAc-branched N-glycans, which are cat-
alyzed by a member of the glycsoyltransferase family, 
N-acetylglucosaminyltransferase-V (GnT-V), have 
been reported to be found in tumor tissues, with in-
creased levels correlating with tumor malignancy and 
poor prognosis15,16). Our recent studies using cell 
lines in which N-glycan processing is genetically al-
tered have demonstrated that defects of N-glycans or 
decreased β1,6GlcNAc-branched N-glycans on β4 in-
tegrin suppress β4 integrin-mediated cancer cell adhe-
sion, migration, invasion, and tumorigenesis10,17). Ad-
ditionally, immunohistochemical analysis has shown 
that colocalization of β1,6GlcNAc-branched N-gly-
cans with β4 integrins are observed in cutaneous SCC 
tissue10). However, the colocalization results in SCC 
tissues do not provide direct evidence that the 
β1,6GlcNAc-branched N-glycans are on β4 integrins 
because the L4-PHA lectin that was used as a probe for 
detecting β1,6GlcNAc-branched N-glycans in the 
analysis also recognizes the β1,6GlcNAc-branched N-
glycans on other proteins. Thus, it could not be de-
termined whether β1,6GlcNAc-branched N-glycans 
on β4 integrin are upregulated in cutaneous SCC tis-
sue. In the present study, we determined the expres-
sion level of β1,6GlcNAc-branched N-glycans on β4 
integrin in normal human skin and cutaneous SCC tis-




Normal human skin and primary cutaneous SCC 
samples were obtained under protocols approved by 
the Ethics Committee of Fukushima Medical Universi-
ty (number 29054), which is guided by local policy, 
national law, and the World Medical Association Dec-
laration of Helsinki. We obtained one normal human 
skin sample and five primary SCC samples from five 
patients with cutaneous SCC. All patients provided 
written informed consent. Fresh samples were col-
lected immediately after surgical resection and stored 
at −80°C. For preparing cell lysates, the samples 
were lysed with a RIPA buffer [1% Nonident P40, 25 
mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% sodium 
deoxycholate, 0.1% SDS] containing 5 mM EDTA, a 
protease inhibitor cocktail (Nacalai Tesque, #25955-
24) and a phosphatase inhibitor cocktail (Nacalai 
Tesque, #07575-51). The samples were homoge-
nized using a plastic pestle and then placed on ice for 
20 min. After centrifugation at 15,000 rpm for 20 
min at 4°C to remove debris, the resultant supernatant 
was collected, aliquoted into 1.5 mL tubes, and stored 
at −80°C until use. The protein concentration of the 
cell lysate was determined using a protein assay kit 
(Nacalai Tesque, #29449-44).
Enzyme-linked immunosorbent assay (ELISA)
For analysis of the β1,6GlcNAc-branched N-gly-
can residues on β4 integrin, wells of an ELISA plate 
(Thermo Fisher Scientific, #445101) were coated with 
50 µL of anti-rat monoclonal Ab against β4 integrin 
(clone 439-9B, BD Transduction Laboratories, 
#555719, 1 : 500) in 50 mM carbonate buffer (15 mM 
Na2CO3, 35 mM NaHCO3, pH 9.6) overnight at 4°C.　
The wells were blocked with 200 µL of 1% BSA in 
PBS for 1 h at 37°C, followed by incubation with 100 
µL of each sample for 1 h at 37°C. The wells were 
then washed three times with TBS containing 0.05% 
Tween 20 (TBS-T), followed by incubation for 1 h at 
room temperature with 100 µL of 5 µg/mL biotinylat-
ed-conjugated L4-PHA (Vector Laboratories, #B-
1115) in TBS-T. After washing three times with 
TBS-T, the wells were incubated with 100 µL of 
horseradish peroxidase-conjugated streptavidin in 
TBS-T for 1 h at room temperature. To estimate the 
amount of β4 integrin in the cell lysates, the wells of 
the ELISA plate were coated with 100 µL of each cell 
lysate sample overnight at 4°C. The wells were 
blocked with 200 µL of 1% BSA in PBS for 1 h at 
37°C, followed by incubation with 100 µL of anti-rab-
bit polyclonal Ab against β4 integrin (H-101, Santa 
Cruz Biotechnology, #sc-9090, 1 : 500) in TBS-T for 
1 h at 37°C. The wells were washed three times with 
TBS-T and incubated with horseradish peroxidase-
conjugated anti-rabbit IgG Ab (Promega, #W401B, 
1 : 2,000) for 1 h at room temperature. After washing 
the wells five times with TBS-T, color development 
proceded using a TMB microwell peroxidase substrate 
system (KPL, #50-76-11), and the reaction was 
stopped by adding 1 M phosphoric acid. The color 
intensity was measured at 450 nm using a microplate 
reader (BioRad, model 680). Then, to investigate 
whether β1,6GlcNAc-branched N-glycans on a β4 in-
tegrin were increased by SCC development, we calcu-
lated the ratio of β1,6GlcNAc-branched N-glycans to 
β4 integrin by dividing the value of β1,6GlcNAc-
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branched N-glycans on β4 integrins by the value of to-
tal β4 integrins.
Statistical analysis
Results were given as mean ± SEM. Statistical 
significance was calculated among the groups using 
one-way ANOVA followed by a Bonferroni post-test, 
with GraphPad Prism Version 5.0a. P < 0.05 was 
considered statistically significant.
Results
Our previous immunohistochemical analysis 
showed that colocalization of β1,6GlcNAc-branched 
N-glycans with β4 integrins was  observed in cutane-
ous SCC tissues10). To examine whether β1,6GlcNAc- 
branched N-glycans on β4 integrin are upregulated 
along with SCC development, we then evaluated the 
ratio of β1,6GlcNAc-branched N-glycans to β4 integ-
rin in the cell lysates from normal skin and cutaneous 
SCC tissues. For that purpose, we developed the 
ELISA systems shown in Figure 1. To estimate the 
amount of β4 integrin, the cell lysates were coated to 
the wells of 96-well ELISA plates and the β4 integrin 
in the cell lysates was detected using an anti-β4 integ-
rin polyclonal Ab (H-101, Figure 1a).　To measure 
the amount of β1,6GlcNAc-branched N-glycans on β4 
integrins, β4 integrin in the cell lysates was captured 
by anti-β4 integrin monoclonal Abs (clone 439-9B) 
coated on plates. Then, β1,6GlcNAc-branched N-
glycans on the captured β4 integrin were detected by 
L4-PHA (Figure 1b), which preferentially binds to 
β1,6GlcNAc-branched N-glycans18).
Next, we performed the modified ELISA assays 
using the cell lysates from normal skin and cutaneous 
SCC tissues to investigate whether β1,6GlcNAc-
branched N-glycans on a β4 integrin were increased 
by SCC development. Then, we calculated the ratio 
of β1,6GlcNAc-branched N-glycans to β4 integrin as 
described in Materials and Methods. SCC samples 
showed a 4.9- to 7.4-fold increase in the ratio of 
β1,6GlcNAc-branched N-glycans to β4 integrin com-
pared to normal skin samples (Figure 2). These re-
sults indicate that the addition of β1,6GlcNAc-
branched N-glycans onto β4 integrin was markedly 
elevated in cutaneous SCC tissue compared to normal 
skin tissue.
Figure 1. Schematic diagram of ELISA in this study. ELISA for detecting β4 integrins (a) and β1,6GlcNAc-
branched N-glycans on β4 integrins (b) in cell lysates. L4-PHA preferentially binds to β1,6GlcNAc-branched N-
glycans.
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Discussion
In the present study, the ELISA assays using cell 
lysates from normal skin and SCC tissues demonstrat-
ed that β1,6GlcNAc-branched N-glycans on β4 integ-
rin were significantly increased in cutaneous SCC tis-
sue compared to normal skin tissue. This finding is 
supported by previous immunohistochemical staining 
data that colocalization of β1,6GlcNAc-branched N-
glycans with β4 integrins were observed in cutaneous 
SCC tissues. Other previous studies reported that de-
fects of N-glycans or decreased β1,6GlcNAc-branched 
N-glycans on β4 integrin suppress β4 integrin-mediat-
ed cancer cell adhesion, migration, invasion, and tu-
morigenesis10,17). Collectively, these data suggest that 
the upregulation of β1,6GlcNAc-branched N-glycans 
on β4 integrin plays pivotal roles in cutaneous SCC 
development and malignant progression.
In the present study, we determined the ratio of 
β1,6GlcNAc-branched N-glycans to β4 integrin, 
which indicates the extent of β1,6GlcNAc-branched 
N-glycans on β4 integrin, using our modified ELISA 
system. The relationship between this ratio and tu-
mor malignancy was unresolved because of our small 
sample size. Further studies using larger sample sizes 
may reveal the relationship between this value and tu-
mor malignancy.
Overexpression of both α6β4 integrin and 
β1,6GlcNAc-branched N-glycans has also been asso-
ciated with poor prognosis in several types of cancers 
such as breast, colon, and esophagus5,15,19-21). Consid-
ering the current findings, it may be interesting to ana-
lyze the number of the β1,6GlcNAc-branched N-gly-
cans on β4 integrin upon development of those tumors.　
The potential for the quantity of β1,6GlcNAc-
branched N-glycans on β4 integrin to become a diag-
nostic marker associated with tumor progression 
should be investigated further.
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